Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that in regard to payers impacting the use of immunotherapies, most payers have decided they will respect the judgment of the Food and Drug Administration, Centers for Medicare & Medicaid Services and the National Comprehensive Cancer Network.
Michael Kolodziej, MD, National Medical Director for Oncology Strategies, Aetna, says that in regard to payers impacting the use of immunotherapies, most payers have decided they will respect the judgment of the Food and Drug Administration, Centers for Medicare & Medicaid Services and the National Comprehensive Cancer Network (NCCN). "If NCCN says the immunotherapies are worth doing we by and large pay for them," said Dr Kolodziej. He notes that due to the high cost of the therapies, they are still regulated. Dr Kolodziej says that the future is uncertain because there will be a shift of responsibility of cost to providers and possibly patients.
This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.
Learning From Past Innovations to Advance Ventilation Use in Respiratory Conditions
May 21st 2024In a keynote presentation at ATS 2024, Hannah Wunsch, MD, MSc, of Weill Cornell Medicine, delved into how the history of breathing support dating back to the 1700s has set the stage for ventilation advances still being made today.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
As AI Utilization Advances in Health Care, Experts at ATS 2024 Share Insights
May 20th 2024Fatima Rodriguez, MD, MPH, from Stanford University, and Matthew DeCamp, MD, PhD, from the University of Colorado, joined Michael Howell, MD, MPH, of Google, on the stage at ATS 2024 to discuss artificial intelligence (AI) in health care.
Read More